Global Flu Shots Market Size By Type (Influenza Virus Split Vaccines, Influenza Virus Subunit Vaccines), By Application (Avian Influenza virus-A, Avian Influenza virus-B), By Region, And Segment Forec...

The Global Flu Shots Market was valued at USD 7.9 billion in 2023 and is projected to surpass USD 12.6 billion by 2031, growing at a CAGR of 6.1% during the forecast period (2023–2031). The market is driven by increasing public awareness of seasonal influenza prevention, supportive government immunization programs, and growing investment in vaccine research and development. Rising global health concerns, especially following the COVID-19 pandemic, have further reinforced the importance of flu vaccination in reducing hospitalizations and healthcare costs.

Drivers

1. Growing Awareness and Government Initiatives:

Governments across the globe are actively promoting annual influenza vaccinations, particularly for high-risk populations such as the elderly, children, and individuals with chronic diseases. Public health campaigns and national immunization schedules significantly boost vaccination rates.

2. Technological Advancements in Vaccine Development:

Innovations such as recombinant and cell-based flu vaccines are improving vaccine efficacy and production speed. These technological advances are encouraging broader adoption across regions and increasing the number of annual doses manufactured.

3. Expansion of Healthcare Access in Emerging Markets:

Emerging economies are increasingly integrating flu shots into primary healthcare services, supported by international organizations like WHO and GAVI. Improved access to healthcare services is propelling demand for flu vaccinations in these regions.

Restraints

1. Vaccine Hesitancy and Misinformation:

Despite awareness efforts, vaccine hesitancy remains a challenge in several regions due to misinformation and distrust in healthcare systems. This affects coverage rates and limits market growth.

2. High Manufacturing Costs and Cold Chain Requirements:

The cost-intensive production process and stringent cold storage requirements pose barriers, especially in resource-limited settings. These limitations can delay distribution and reduce vaccine availability.

Opportunity

1. Pandemic Preparedness and Global Surveillance Programs:

Increased investment in pandemic preparedness and global influenza surveillance systems presents significant opportunities. Governments and organizations are focusing on stockpiling and rapid deployment capabilities, boosting demand for flu shots.

2. Development of Universal Flu Vaccines:

Research into universal influenza vaccines that provide long-term protection against multiple strains offers promising future growth. Breakthroughs in this space can revolutionize the flu vaccine market and reduce the need for annual updates.

Market by System Type Insights

By system type, quadrivalent flu vaccines held the largest market share in 2023. These vaccines offer protection against four different flu viruses—two influenza A viruses and two influenza B viruses—and are preferred due to their broader immunization profile. Trivalent vaccines, although still used in certain regions, are witnessing a gradual decline due to their limited coverage.

Market by End-use Insights

In terms of end-use, the hospital and clinic segment accounted for the largest revenue share in 2023. These healthcare settings serve as primary vaccination sites due to their accessibility and trustworthiness. The pharmacy-based vaccination segment is also experiencing rapid growth, especially in developed markets, due to convenience and expanding immunization authority among pharmacists.

Market by Regional Insights

Regionally, North America dominated the Global Flu Shots Market in 2023, driven by robust healthcare infrastructure, high vaccination coverage, and strong government support. Europe followed closely due to similar healthcare frameworks and immunization mandates. Meanwhile, Asia-Pacific is projected to witness the highest CAGR during the forecast period, with increasing healthcare expenditure, public awareness, and flu surveillance initiatives in countries like China and India.

Competitive Scenario

Key players in the Global Flu Shots Market include:

Sanofi Pasteur

GlaxoSmithKline plc

Seqirus (a CSL company)

Moderna, Inc.

AstraZeneca

Novavax, Inc.

Serum Institute of India

Bharat Biotech

These companies are actively engaged in expanding their vaccine portfolios, forming strategic partnerships, and investing in R&D for next-generation flu vaccines. For instance:

In 2024, Sanofi Pasteur launched a high-dose quadrivalent flu vaccine targeted at seniors in Europe.

Moderna announced in 2023 the initiation of Phase 3 trials for its mRNA-based flu shot, combining it with COVID-19 boosters for seasonal use.

Seqirus expanded its manufacturing facility in the U.S. in 2022 to meet the rising global demand for influenza vaccines.

Scope of Work – Global Flu Shots Market

Key Market Developments

April 2023: Moderna initiated late-stage trials for its combination flu and COVID-19 vaccine using mRNA technology.

September 2023: Sanofi Pasteur received expanded approval in the U.S. for its high-dose quadrivalent vaccine for individuals aged 50 and above.

December 2024: GlaxoSmithKline launched an educational campaign across Europe to combat vaccine hesitancy and improve seasonal flu vaccination rates.

FAQs

1. What is the current market size of the Global Flu Shots Market?

The Global Flu Shots Market was valued at USD 7.9 billion in 2023.

2. What is the major growth driver of the Global Flu Shots Market?

Key growth drivers include increased public awareness, government immunization programs, and advancements in flu vaccine technology.

3. Which is the largest region during the forecast period in the Global Flu Shots Market?

North America is expected to remain the largest region due to strong infrastructure and high vaccine uptake.

4. Which segment accounted for the largest market share in the Global Flu Shots Market?

The quadrivalent flu vaccines segment accounted for the largest share by system type, while hospitals and clinics led by end-use.

5. Who are the key market players in the Global Flu Shots Market?

Sanofi Pasteur, GlaxoSmithKline, Seqirus, Moderna, AstraZeneca, Novavax, and Serum Institute of India are among the key players.